Boston Scientific Unlikely to Meet 2026 Sales, Profit Forecasts After Cyberattack
Boston Scientific announced it is unlikely to meet its third-quarter and full-year 2026 sales and adjusted profit forecasts due to a cybersecurity incident that disrupted global operations. The unauthorized activity on the company’s IT systems was first detected on August 25, causing network outages affecting manufacturing, order processing, and shipments. As of now, major distribution centers are operating at or above normal levels, sterilization facilities are functional, and most manufacturing sites have resumed production. The cyberattack has delayed Boston Scientific's ability to meet its financial targets for the year, including adjusted earnings per share between $3.28–$3.32 and net sales growth of 5.5%–6.5%. The company expects some recovery as operations ramp up but remains uncertain about the full impact on revenue. This incident is part of a growing trend of cyberattacks targeting healthcare companies, including peers like Abbott Laboratories, Stryker, Medtronic, Clover Health, and Novo Nordisk. Boston Scientific plans to provide an update when it reports third-quarter results on October 28.
Tickers: $ABT $BSX $MDT $NVO $SYK
Topics: cyberattack financial_forecast_update medical_devices